A new study published in the journal of PloS One showed that although reoperative therapy with evolocumab with rosuvastatin ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide, primarily resulting from an abrupt coronary artery occlusion that deprives myocardial tissue of oxygen.

- Reduced inflammation at the site of myocardial infarction and improved heart function demonstrated. Novel therapy to modulate immune response with apoptotic cell-derived nanovesicles. Myocardial ...

Find out more about how loss of Y chromosome in ageing males was linked to higher heart attack risk in a large prospective ...

Slower heart rate recovery before PCI independently predicts periprocedural myocardial infarction and may improve cardiac risk assessment.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Myocardial infarction (MI) triggers adverse remodeling mechanisms, thus leading to heart failure. Since ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...

Patients with elevated epicardial adipose tissue volume (EATV) exhibit greater acute myocardial injury following acute myocardial infarction.

Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...

Patients recently diagnosed with cancer show an increased risk for major bleeding after myocardial infarction, with the risk ...